Format

Send to

Choose Destination
ACS Nano. 2013 Apr 23;7(4):2878-82. doi: 10.1021/nn4015399.

Design principles for clinical efficacy of cancer nanomedicine: a look into the basics.

Author information

1
Laboratory of Nanomedicine, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard-MIT Division of Health Science Technology, Harvard Medical School, Dana Farber Cancer Center, 65 Landsdowne Street, Room 317, Boston, Massachusetts 02139, United States. shiladit@mit.edu

Abstract

With recent advances in cancer nanomedicine, there is an increasing expectation for clinical translation. However, what are the parameters of a nanomedicine that will define clinical success, which will be measured by increased efficacy and not just ease of delivery or reduction in toxicity? In this Perspective, we build on a fundamental study by Stefanick et al. on the significance of the design principles in the engineering of a nanomedicine, such as peptide-PEG-linker length and ligand density in cellular uptake of liposomal nanoparticles. We address additional design parameters that can potentially facilitate clinical translation as well as how emerging insights into tumor biology will inspire next-generation cancer nanomedicines.

PMID:
23607425
PMCID:
PMC3876731
DOI:
10.1021/nn4015399
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center